Personalized Immunotherapy for Tumor Diseases and Beyond

Molecular Targeting Checkpoint in Cancer- Foundation of Personalized Immunotherapy

Author(s): Shuzhen Tan and Xiao Zhu

Pp: 70-79 (10)

DOI: 10.2174/9789811482755120010008

* (Excluding Mailing and Handling)


Currently, in the study of new anti-tumor therapies, the suppression of tumor growth through target checkpoints is a breakthrough in this treatment method. Now, this has gradually become the focus of in-depth research. By acting on specific molecular targets, tumor cells can be inhibited through information transmission in the human immune pathway, thereby inhibiting their growth and proliferation. Molecularly targeted checkpoint inhibitors can specifically kill tumors within the tumor microenvironment (TME), inhibiting the occurrence and development of tumors. On the other hand, they can target and inhibit other molecules, so that they can restore immune cell activity, and improve the body's anti-tumor immune function, namely the tumor immune microenvironment (TIME). At present, molecular target checkpoints that have been increasingly studied within TIME include PD-1, PD-L1, CTLA-4, TIM- 3, LAG-3, and Siglec-15. Corresponding molecular target inhibitors have been prepared for these molecular targets, and thus they have been increasingly applied to the clinic. Although these inhibitors have unavoidable adverse reactions and limitations in their scope of application in certain types of tumors, they still offer hope for the successful elimination of tumors.

Keywords: Hepatocellular Carcinoma (HCC), Immune checkpoint inhibitor (ICI), Major histocompatibility complex (MHC), Mutation allele frequency (MAF), Non-small cell lung cancer (NSCLC), Regulatory T-cells (Treg), Small cell lung cancer (SCLC), T-cell receptor (TCR), Tumor immune microenvironment (TIME).

Related Journals
Related Books
© 2024 Bentham Science Publishers | Privacy Policy